BARDINI, MICHELA
 Distribuzione geografica
Continente #
NA - Nord America 4.544
EU - Europa 2.571
AS - Asia 2.320
SA - Sud America 388
Continente sconosciuto - Info sul continente non disponibili 216
AF - Africa 52
OC - Oceania 1
Totale 10.092
Nazione #
US - Stati Uniti d'America 4.294
IT - Italia 864
SG - Singapore 791
CN - Cina 608
RU - Federazione Russa 304
HK - Hong Kong 290
DE - Germania 279
BR - Brasile 267
VN - Vietnam 239
SE - Svezia 238
IE - Irlanda 226
CA - Canada 202
UA - Ucraina 142
GB - Regno Unito 115
IN - India 79
FR - Francia 78
ES - Italia 66
FI - Finlandia 60
BD - Bangladesh 51
NL - Olanda 51
AT - Austria 41
AR - Argentina 39
KR - Corea 37
EC - Ecuador 32
ID - Indonesia 32
IQ - Iraq 31
MX - Messico 23
TR - Turchia 23
SA - Arabia Saudita 21
PL - Polonia 20
DK - Danimarca 18
BE - Belgio 17
JP - Giappone 17
ZA - Sudafrica 17
UZ - Uzbekistan 16
CO - Colombia 15
PT - Portogallo 13
PH - Filippine 12
PK - Pakistan 12
VE - Venezuela 12
CH - Svizzera 10
KE - Kenya 8
JM - Giamaica 7
LT - Lituania 7
PE - Perù 7
PY - Paraguay 7
TW - Taiwan 7
EG - Egitto 6
KZ - Kazakistan 6
JO - Giordania 5
NP - Nepal 5
RO - Romania 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
GR - Grecia 4
IL - Israele 4
IR - Iran 4
MA - Marocco 4
MY - Malesia 4
AO - Angola 3
AZ - Azerbaigian 3
BG - Bulgaria 3
CL - Cile 3
CZ - Repubblica Ceca 3
GT - Guatemala 3
NO - Norvegia 3
OM - Oman 3
TH - Thailandia 3
CI - Costa d'Avorio 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
EU - Europa 2
GD - Grenada 2
HN - Honduras 2
LB - Libano 2
LY - Libia 2
NI - Nicaragua 2
PA - Panama 2
QA - Qatar 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BT - Bhutan 1
BY - Bielorussia 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
HR - Croazia 1
KH - Cambogia 1
KW - Kuwait 1
LK - Sri Lanka 1
MW - Malawi 1
NG - Nigeria 1
PR - Porto Rico 1
PS - Palestinian Territory 1
Totale 9.875
Città #
Ann Arbor 469
Ashburn 454
Singapore 448
Hong Kong 281
Chandler 246
Fairfield 244
San Jose 237
Dublin 224
Woodbridge 210
Houston 209
Milan 200
Frankfurt am Main 167
Wilmington 147
Toronto 134
Jacksonville 132
New York 129
Beijing 107
Dearborn 94
Seattle 93
Santa Clara 85
Ho Chi Minh City 83
Cambridge 74
Los Angeles 72
Chicago 69
Princeton 64
Council Bluffs 62
Dallas 62
Rome 60
The Dalles 59
Hefei 55
Nanjing 52
Hanoi 50
Lauterbourg 37
Moscow 35
Vienna 35
Seoul 34
São Paulo 32
Shanghai 31
Lawrence 27
Orem 26
Barcelona 23
Buffalo 23
Columbus 23
Guangzhou 23
Brooklyn 22
Chennai 22
Jakarta 21
Lachine 21
London 21
San Diego 21
Munich 20
Naples 19
Altamura 18
Helsinki 18
Andover 17
Boardman 17
Denver 17
Shenyang 17
Phoenix 16
Warsaw 16
Montreal 15
Nanchang 15
Tashkent 15
Brussels 14
Fremont 14
Quito 14
Stockholm 14
Tianjin 14
Bari 12
Hangzhou 12
Rio de Janeiro 12
Sesto San Giovanni 12
Boston 11
Dong Ket 11
Florence 11
Guayaquil 11
Johannesburg 11
Lissone 11
Manchester 11
Nuremberg 11
Poplar 11
Turku 11
Norwalk 10
Salt Lake City 10
Tokyo 10
Baghdad 9
Brasília 9
Jinan 9
Riyadh 9
Allentown 8
Atlanta 8
Changsha 8
Jeddah 8
Lappeenranta 8
Nairobi 8
Newark 8
Perugia 8
Philadelphia 8
Zurich 8
Ankara 7
Totale 6.150
Nome #
Infant ALL with MLL-AF4 is sustained by t(4;11) as the sole genetic abnormality, and it is initiated in mice by phenotypically and functionally distinct leukemic stem cell subsets 658
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia 424
The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL 386
Unravelling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis 384
NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLL-r B-ALL by regulating NR3C1 expression 357
NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL 351
Antileukemic efficacy of BET inhibitor in a preclinical mouse model of MLL-AF4 + infant ALL 351
Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse 313
Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants 311
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120 307
LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients 283
Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement 279
Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening 271
DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4 267
Characterization of bortezomib-induced peripheral neuropathy in an immune-suppressed murine model 261
Effects of C/EBPalpha and C/EBPbeta in BCR/ABL-Expressing Cells: Differences and Similarities 258
Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency 247
Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis 245
In Infant ALL with t(4;11)/MLL-AF4 Multiple and Phenotypically Distinct CD19+ BM Subsets Initiate Leukemia in NOD/SCID Mice 228
The silent mutational landscape of infant MLL-AF4 pro-B acute lymphoblastic leukemia 223
Implementation of array based whole-genome high-resolution technologies confirms the absence of secondary copy-number alterations in MLL-AF4-positive infant ALL patients 221
Prenatal origin of NUTM1 gene rearrangement in infant B-cell precursor acute lymphoblastic leukaemia 220
Correction to: NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL (Leukemia, (2018), 32, 3, (633-644), 10.1038/leu.2017.294) 211
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease 209
Generazione di modelli in vivo per l'identificazione e lo studio di clonalità delle cellule staminali leucemiche nella LAL infant MLL-AF4 positiva 208
Expression of CCL9/MIP-1bold italic gamma is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells 207
Unique genomic profile of infant all patients 206
LAL infant introduces a new specific genomic profile 202
Infant ALL patients carrying t(4;11) have a different genotypic profile than older ALL children 198
In infant all with t(4;11)/mll-af4 multiple and phenotypically distinct bm subsets initiate leukemia into nod/scid mice 196
The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia 196
Identification and characterization of candidate L-ICs IN MLL-AF4 infant all 195
Oligoclonal origin of functionally distinct leukemic stem cells in infant acute lymphoblastic leukemia 191
Infant ALL patients carrying t(4;11) have a different genotypic profile than older ALL children 191
Metabolic adaptation of acute lymphoblastic leukemia to the central nervous system microenvironment is dependent on Stearoyl CoA desaturase 189
Infant ALL patients carrying t(4;11) have a different genotypic profile than older ALL children 189
Inducible activation of C/EBPb, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells 176
Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients 166
The EGR3 regulome of infant KMT2A-r acute lymphoblastic leukemia identifies differential expression of B-lineage genes predictive for outcome 117
Totale 10.092
Categoria #
all - tutte 31.419
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.419


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022373 0 0 35 30 42 68 14 24 19 46 20 75
2022/2023920 86 275 86 74 51 155 14 55 76 1 35 12
2023/2024660 26 30 41 35 75 178 122 31 44 14 20 44
2024/20251.480 79 120 65 90 93 39 110 35 172 266 141 270
2025/20263.749 438 195 311 468 430 190 418 187 251 361 264 236
2026/2027266 129 131 6 0 0 0 0 0 0 0 0 0
Totale 10.092